The interim analysis of the Phase III TULIP-SC trial reveals that AstraZeneca’s SAPHNELO® offers a significant advancement in lupus treatment, demonstrating a notable reduction in disease activity. This positive outcome not only reinforces the drug’s efficacy but also underscores AstraZeneca’s commitment to addressing unmet needs in the systemic lupus erythematosus market.
WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca’s SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The safety profile observed in the interim analysis was consistent with the known clinical profile of SAP
Source: Original Press Release
